Aromatase inhibitors and their application in breast cancer treatment

Steroids

Volumn 65, Issue 4, 2000, Pages 171-179

  Brodie, Angela M H ^a   Njar, Vincent C O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase; Breast cancer; Inhibitors

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; NONHUMAN; REVIEW;

ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; MICE; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 0034106931     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(99)00104-X     Document Type: Review

References (72)

1. McGuire W.L. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. Iacobelli S., et al. Hormones and Cancer. 1980;337-344 Raven Press, New York.
2. Hemsell D.L., Gordon J., Breuner P.F., Siiteri P.K. Plasma precursors of estrogen II. Correlation of the extent of conversion of plasma androstenedione to estrone with age . J Clin Endocr Metab. 38:1974;476-479.
3. Schwarzel W.C., Kruggel W., Brodie H.J. Studies on the mechanism of estrogen biosynthesis. VII. The development of inhibitors of the enzyme system in the human placenta. Endocrinology. 92:1973;866-880.
4. Brodie A.M.H., Schwarzel W.C., Shaikh A.A., Brodie H.J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen dependent processes in reproduction and breast cancer. Endocrinology. 100:1977;1684-1694.
5. Cole M.P., Jones C.T.A., Todd I.D.H. A new antiestrogenic agent in late breast cancer an early appraisal of ICI 46,474 . Br J Cancer. 25:1971;270-275.
6. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15.
7. Jordan V.C. Tamoxifen toxicities and drug resistance during the treatment and prevention of breast cancer . Ann Rev Pharmacol Toxicol. 35:1995;195-211.
8. Fisher B, Constantino JP, Wickerham DL, et al., other National Surgical Adjuvant Breast and Bowel Project Investigators. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
9. Fornander T., Hellstrom A.C., Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 815:1993;1850-1855.
10. Harper M.J.K., Wapole A.L. A new derivative of triphenylethylene effect on implantation and mode of action in rats . J Reprod Fertil. 13:1967;101-119.
11. Roselli C.E., Horton L.E., Resko J.A. Distribution and regulation of aromatase activity in the rat hypothalamus and limbic systems. Endocrinology. 117:1985;2471-2477.
12. Payne A.H., Perkins L.M., Georgiou M., Quinn P.G. Intratesticular site of aromatase activity and possible function of testicular estradiol. Steroids. 50:1987;435-448.
13. Brodie A.M.H., Inkster S.E. Aromatase in the human testis. J Steroid Biochem Mol Biol. 44:1993;4-6.
14. Longcope C., Pratt J.H., Schneider S.H., Fineberg S.E. Aromatization of androgens by muscle and adipose tissue in vivo. J Clin Endocrinol Metab. 46:1978;146-152.
15. Baird D.T., Horton R., Longcope C., Tait J.F. Steroid dynamics under steady-state conditions. Recent Prog Horm Res. 25:1969;611-634.
16. Bulun SE, Rosenthal IM, Brodie AMH, et al. Use of tissue specific promoters in the regulation of aromatase cytochrome P450 gene expression in human testicular and ovarian sex cord tumors, as well as in normal fetal and adult gonads. J Clin Endocriol Metab 1993a;77:1616-21.
17. McNatty K.P., Makris A., De Grazia C., Osathanondh R., Ryan K.J. The production of progesterone, androgens, and estrogens by granulosa cells, thecal tissue, and stromal tissue from human ovaries in vitro. J Clin Endocrinol Metab. 49:1979;687-699.
18. Inkster S.E., Brodie A.M.H. Expression of aromatase cytochrome P-450 in premenopausal and postmenopausal human ovaries an immunocytochemical study . J Clin Endocrinol Metab. 73:1991;717-726.
19. Naftolin F., Ryan K.J., Davis I.J., et al. The formation of estrogen by central neuroendocrine tissues. Recent Prog Horm Res. 31:1975;295-319.
20. Inkster S.E., Brodie A.M.H. Immunocytochemical studies of aromatase in early and full term human placental tissues comparison with biochemical assays . Biol Reprod. 41:1989;889-898.
21. Longcope C. Peripheral aromatization studies on controlling factors . Steroids. 50:1987;253-267.
22. Szyczak J., Milewicz A., Thijssen J.H.H., Blankenstein M.A., Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids. 63:1998;319-321.
23. van Landegham A.A.J., Portman J., Nabauurs M. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:1985;2900-2906.
24. th International Congress on Hormonal Steroids, Quebec City, Canada 1998.
25. Lu Q., Nakmura J., Savinov A., et al. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology. 137:1996;3061-3068.
26. Bulun S.E., Simpson E. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat. 30:1994;19-29.
27. Mahendroo M.S., Mendelson C.R., Simpson E.R. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P-450 gene expression in human adipose tissue. J Biol Chem. 268:1993;19463-19470.
28. Harada N., Utsumi T., Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA. 90:1993;11313-11316.
29. Honda S., Harada N., Takagi Y. Novel exon 1 of the aromatase gene specific for transcripts in human brain. Biochem Biophys Res Comm. 198:1994;1153-1160.
30. Toda K., Simpson E.R., Mendelson C.R., Shizuta Y., Kilgore M.W. Expression of the gene encoding aromatase cytochrome P-450 (CYP19) in fetal tissues. Mol Endocrinol. 8:1994;210-217.
31. Simpson E.R., Mahendroo M.S., Nichols J.E., Bulun S.E. Regulation of aromatase gene expression relationship to breast cancer . Motta M., Serio M. Sex hormones and antihormones in endocrine dependent pathology basic and clinical aspects . 1994;269-279 Elsevier, Amsterdam, The Netherlands.
32. Simpson E.R., Ackerman G.E., Smith M.E., Mendelson C.R. Estrogen formation in stromal cells of adipose tissue of women induction of glucocorticosteroids . Proc Natl Acad Sci USA. 78:1981;5690-5694.
33. Mendelson C.R., Cleland W.H., Smith M.E., Simpson E.R. Regulation of aromatase activity of stromal cells derived from human adipose tissue. Endocrinology. 111:1982;1077-1085.
34. Thompson E.A., Sitteri P.K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem. 249:1974;5364-5367.
35. Thompson E.A., Sitteri P.K. The involvement of human placental microsomal cytochrome P-450 in aromataization. J Biol Chem. 249:1974;5373-5378.
36. Akhtar M., Njar V.C.O., Wright J.N. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J Steroid Biochem Mol Biol. 44:1993;375-387.
37. Cole P.A., Robinson C.H. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem. 33:1990;2933-2944.
38. Corbin C., Graham-Lorence S., McPhaul M., Mason J., Mendelson C., Simpson E. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci USA. 85:1988;8948-8952.
39. Nebert DW, Nelson DR, Coon MJ, et al. The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Mol Biol 1991;10:1-14.
40. Brodie A.M.H., Schwarzel W.C., Shaikh A.A., Brodie H.J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen dependent processes in reproduction and breast cancer. Endocrinology. 100:1974;1684-1694.
41. Brodie A.M.H., Schwarzel W.C., Brodie H.J. Studies on the mechanism of estrogen biosynthesis in the rat ovary-1. J Steroid Biochem. 7:1976;787-793.
42. Brodie A.M.H., Garrett W.M., Hendrickson J.R., Tsai-Morris C.H. Effects of 4-hydroxyandrostenedione and other compounds in the DMBA breast carcinoma model. Cancer Res. 42:1982;3360s-3364s.
43. Brodie AMH, Garrett WM, Hendrickson JR, Marcotte PA., Robinson CH. Inactivation of aromatase activity in placental and ovarian microsomes by 4-hydroxyandrostene-3,17-dione and 4-acetoxyandrostene-3,17-dione. Steroids 1981;38:693-702.
44. Brodie A.M.H., Longcope C. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy-and 4-acetoxy-androstene-3,17-dione. Clin Endocrin. 106:1980;19-21.
45. Jones AL, MacNeill F, Jacobs S, Lønning PE, Doesett M, Powles TJ. The influence of intramuscular (i.m.) 4-hydroxyandrostenedione on peripheral aromatization in breast cancer patients. Eur J Cancer 1992;28A:1712-6.
46. Dowsett M., Cunningham D.C., Stein R.C., et al. Dose-related endocrine effects and pharmacokinetics of oral and i. m. 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 49:1989;1306-1312.
47. Coombes R.C., Goss P., Dowsett M., Gazet J.C., Brodie A.M.H. 4-Hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer. Lancet. 2:1984;1237-1239.
48. Goss P.E., Coombes R.L., Powles T.J., Brodie A.M.H. Treatment of advanced post-menopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione-Phase 2 report. Cancer Res. 46:1986;4823-4826.
49. Dowsett D.M., Coombes R.C. Second generation aromatase inhibitor, 4-OHA. Breast Cancer Res Treat. 30:1994;81-87.
50. Possinger K, Jonat W, Hoffken K. Formestane in the treatment of advanced postmenopausal breast cancer. Ann Oncol 1994;5:S7-S10.
51. Bajetta E, Zilemba N, Norersco C, Bichisoa E. Formestane: effective therapy in postmenopausal women with advanced breast cancer. In: Nagel G, Possinger K, editors. Selective Aromatase Inhibitors - Improved Quality of Life for Metastatic Breast Cancer Patients. Excerpta Oncol Ciba, Ciba-Geigy Verlag, Wehr/Barden, 1996. pp. 51-6.
52. Cunningham D., Powles T.J., Dowsett M., et al. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol. 20:1987;253-255.
53. Carrion R.P., Candel V.A., Calabresi F., et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol. 7:1994;S19-S24.
54. Brueggermeier R.W., Li P.K., Snider C.E., Darby M.V., Katlic N.E. 7α-Substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase. Steroids. 50:1987;163-178.
55. Johannessen D.C., Engan T., di Salle E., et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients a phase I study . Clin Cancer Res. 1997;1101-1108.
56. Henderson D., Norbisrath G., Kerb U. 1-Methly-1,4-androstadiene-3,17-dione (SH489) characterization of an irreversible inhibitor of estrogen biosynthesis . J Steroid Biochem. 24:1986;303-306.
57. Metcalf B.W., Wright C.L., Burkhart J.P., Johnston J.O. Substrate-induced inactivation of aromatase by allenic and acetylenic steroids. J Amer Chem Soc. 103:1981;3221-3222.
58. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998: 4:2089-93.
59. Santen R.J., Worgul T.J., Lipton A., et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma correlation of clinical and hormonal responses . Ann Intern Med. 96:1982;94-101.
60. Plourde P.V., Dyroff M., Dukes M. Arimidex a potent and selective fourth-generation aromatase inhibitor . Breast Cancer Res Treat. 30:1994;103-111.
61. Bhatnagar A.S., Hausler A., Trunet P., Schieweck K., Lang M., Bowman P. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 37:1990;1021-1027.
62. Jonat W, Howell A, Blomqvist C, et al. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole ('ARIMIDEX') with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32A:404-12.
63. Buzdar A, Jonat W, Howell A, Yin H, Lee D. Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. The Arimidex International study Group, Houston, TX, Kiel, Germany, Manchester, UK, Wilmington, DE, Macclesfield, UK, (Arimidex is a trademark, property of Zeneca Limited). Proceedings of American Society of Clinical Oncology 1997;16:156a.
64. Marty M, Gershanovich M, Campos B, et al. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with anti-estrogens. The Letrozole International Trial group (AR/BC3). Proceedings of ASCO 1997;16:156a.
65. Yue W., Zhou D., Chen S., Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 54:1994;5092-5095.
66. Yue W., Wang J., Savinov A., Brodie A. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res. 55:1995;3073-3077.
67. Yue W., Wang J., Hamilton C.J., Demers L.M., Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 58:1998;927-932.
68. Lu Q., Yue W., Wang J., Lui Y., Long B., Brodie A. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat. 50:1998;63-71.
69. Brodie A., Lu Q., Liu Y., Long B., Wang J.P., Yue W. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology. 12:1998;29-33.
70. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999;57:183-92.
71. Geisler J., Johannessen D.C., Anker G., Lønning P.E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients clinical and endocrine effects . Eur J Cancer. 32:1996;789-792.
72. Murray R., Pitt P. Aromatase inhibition with 4-OH androtenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat. 35:1995;249-253.